Actelion to discuss second quarter 2010 financial results
Actelion Pharmaceuticals Ltd / Actelion to discuss second quarter 2010 financial results processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.
Dear member of the investment community
Actelion Ltd will announce the second quarter 2010 financial results on Tuesday,
20 July 2010, at 07.00 hrs CEST / 06.00 hrs BST / 01.00 a.m. EDT. The company
will also issue the Half-Year report at the same time. An investor conference
call & webcast will be held at 14.00 hrs, CEST to discuss the results, as well
as to provide an update on the development pipeline.
20 July 2010 14.00 hrs - 15.00 hrs Basel (CET)
Â 13.00 hrs - 14.00 hrs UK (GMT)
Â 08.00 a.m. - 09.00 a.m. US (EST)
Conference Call Connect #:
Dial-in participants should start calling the number below 10-15 minutes before
the conference is due to start.
Dial: Europe: +41 (0)44 580 64 03
Â UK: +44 (0)203 147 47 52
Â US: +1 866 9311 573
Listen-Only with possibility to open individual lines during Q&A session.
Participants will be asked for their Name and Company.
Webcast participants should visit the Actelion websitehttp://www.actelion.com/
10-15 minutes before the conference is due to start. If you experience any
access problems go directly to the
Listen-Only with possibility to ask individual questions by clicking on the Q&A
Participants will be asked to provide their Name and Company.
The archived Investor Webcast will be available for replay
approximately 60 minutes after the call has ended.
--- End of Message ---
Actelion Pharmaceuticals Ltd
Gewerbestrasse 16 Allschwil Switzerland
Press Release PDF: http://hugin.info/131801/R/1431981/378265.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
All reproduction for further distribution is prohibited.
Source: Actelion Pharmaceuticals Ltd via Thomson Reuters ONE